Clinical Trial Update: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating Rituximab (MabThera) in rheumatoid arthritis patients with inadequate response to methotrexate; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2014-06-10